The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Phase I study of TNB-383B in R/R multiple myeloma
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the design and findings of the ongoing Phase I first-in-human dose-escalation/expansion study of TNB-383B, a novel bispecific antibody targeting BCMA and CD3 in patients with relapsed/refractory (R/R) multiple myeloma (NCT03933735). There are currently 118 patients enrolled in this study, and they have received a median of six prior lines of therapy. In the patient group treated with a 40 mg or higher dose, it appeared that TNB-383B was well tolerated, with adverse events such as hematological toxicity and low-grade cytokine release syndrome (CRS) observed in over 50% of patients. Overall response rates (ORR) were 81% among patients in the dose-escalation phase after a median follow-up of 8 months and 53% in patients in both the dose-expansion and dose-escalation phases after a median follow-up of 4 months. In addition, over half of triple-class refractory patients responded to therapy. Overall, TNB-383B appears to be effective and safe in this heavily pre-treated patient population. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
